Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Predicting Survival After Liver Transplant

By HospiMedica staff writers
Posted on 20 Dec 2006
A new model based on specific characteristics of the donor and the recipient may help predict survival after liver transplantation, according to a new study.

George Ioannou, M.D., M.S., of the Veterans Affairs (VA) Puget Sound Health Care System (Seattle, WA, USA) sought to identify donor and recipient characteristics that are important predictors of graft survival following liver transplantation. More...
Using information provided by the U.S. united network for organ sharing (UNOS; Richmond, VA, USA), he identified all patients who had a liver transplant between 1994 and 2003. He did not include patients who had donors under age 10 or over age 75, living donors, split-liver donors, non-heart-beating donors, or donors with serum sodium concentration greater than 170 mmoles/l. He also excluded patients with multiple organ transplants, previous liver transplants, and incomplete information.

For the 20,301 patients who remained, including 6,477 with hepatitis C (HCV), Dr. Ioannou used statistical models to examine the relationship between donor and recipient characteristics and survival after transplant. He then created two models that predict survival after liver transplant--one for patients without HCV and one for those with HCV. He validated the models using data from patients not included in their derivation.

The study found that the donor age, cold ischemia time, recipient model end-stage liver disease (MELD) score, and cause of liver disease have the greatest impact on survival. However, the best model for patients without HCV included donor age, cold ischemia time, gender, race/ethnicity, recipient age, body mass index (BMI), MELD score, status at time of transplantation, diabetes mellitus, cause of liver disease, and serum albumin. For patients with HCV, the best model included the same donor characteristics, and all recipient characteristics except cause of liver disease and serum albumin. The findings were published in the November 2006 issue of Liver Transplantation.

"Risk scores and predicted survivals determined from such models may be an objective way to assess the risk of a given liver donor, recipient, or donor/recipient combination,” said Dr. Ioannou. "This model could be used to inform liver transplant candidates and their doctors what post-transplant survival would be expected when a given donor is offered and may be particularly helpful in marginal or high risk donors.”



Related Links:
Puget Sound Health Care System
United Network for Organ Sharing

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.